Targeting apoptosis for anticancer therapy

Seminars in Cancer Biology

Volumn 31, Issue , 2015, Pages 84-88

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Cancer; Cell death; Death receptor; Mitochondria

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; KU ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MCL 1; RAS PROTEIN; RETINOIC ACID; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; VENETOCLAX; ANTINEOPLASTIC AGENT; CASPASE 3; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CASPASE 8 GENE; CELL DEATH; CELL SURVIVAL; DNA DAMAGE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVATION; EPIGENETICS; GENE SILENCING; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; UPREGULATION; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84923217162     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.05.002     Document Type: Review

References (64)

1. Lockshin R.A., Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007, 11:1214-1224.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009, 124:511-515.
4. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
5. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008, 19:325-331.
6. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012, 11:109-124.
7. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
8. Li L.Y., Luo X., Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001, 412:95-99.
9. Friesen C., Fulda S., Debatin K.M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 1997, 11:1833-1841.
10. Jin Z., McDonald E.R., Dicker D.T., El-Deiry W.S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004, 279:35829-35839.
11. Pai S.I., Wu G.S., Ozoren N., Wu L., Jen J., Sidransky D., et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58:3513-3518.
12. Dechant M.J., Fellenberg J., Scheuerpflug C.G., Ewerbeck V., Debatin K.M. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 2004, 109:661-667.
13. Beltinger C., Kurz E., Bohler T., Schrappe M., Ludwig W.D., Debatin K.M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998, 91:3943-3951.
14. Beltinger C., Bohler T., Karawajew L., Ludwig W.D., Schrappe M., Debatin K.M. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 1998, 102:722-728.
15. Sheikh M.S., Huang Y., Fernandez-Salas E.A., El-Deiry W.S., Friess H., Amundson S., et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999, 18:4153-4159.
16. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett 2009, 281:128-133.
17. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535.
18. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877.
19. Harada K., Toyooka S., Shivapurkar N., Maitra A., Reddy J.L., Matta H., et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002, 62:5897-5901.
20. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003, 10:356-364.
21. Grotzer M.A., Eggert A., Zuzak T.J., Janss A.J., Marwaha S., Wiewrodt B.R., et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000, 19:4604-4610.
22. Fulda S. Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Opin Ther Targets 2013, 17:195-201.
23. Fulda S., Meyer E., Debatin K.M. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000, 60:3947-3956.
24. Longley D.B., Wilson T.R., McEwan M., Allen W.L., McDermott U., Galligan L., et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006, 25:838-848.
25. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
26. Chow L.Q., Eckhardt S.G., Gustafson D.L., O'Bryant C., Hariharan S., Diab S., et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase 1 and PK study. J Clin Oncol 2006, 24:2515.
27. Herbst R.S., Mendolson D.S., Ebbinghaus S., Gordon M.S., O'Dwyer P., Lieberman G., et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006, 24:3013.
28. Patnaik A., Wakelee H., Mita M., Fitzgerald A., Hill M., Fox N., et al. HGS-ETR2 - a fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors. Proceedings Am Soc Clin Oncol 42nd Annual Meeting 2006, A3012.
29. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007, 25:1390-1395.
30. Takimoto R., El-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19:1735-1743.
31. Meng R.D., El-Deiry W.S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001, 262:154-169.
32. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003, 22:1807-1816.
33. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
34. Azijli K., Yuvaraj S., Peppelenbosch M.P., Wurdinger T., Dekker H., Joore J., et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci 2012, 125:4651-4661.
35. Panner A., James C.D., Berger M.S. Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005, 25:8809-8823.
36. Pathil A., Armeanu S., Venturelli S., Mascagni P., Weiss T.S., Gregor M., et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006, 43:425-434.
37. Bangert A., Cristofanon S., Eckhardt I., Abhari B.A., Kolodziej S., Hacker S., et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012, 31:4677-4688.
38. Kerr E., Holohan C., McLaughlin K.M., Majkut J., Dolan S., Redmond K., et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 2012, 19:1317-1327.
39. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000, 60:4315-4319.
40. Casciano I., De Ambrosis A., Croce M., Pagnan G., Di Vinci A., Allemanni G., et al. Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death Differ 2004, 11:131-134.
41. Fulda S., Debatin K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002, 21:2295-2308.
42. Jiang M., Zhu K., Grenet J., Lahti J.M. Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta 2008, 1783:1055-1067.
43. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984, 226:1097-1099.
44. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
45. Kitada S., Pedersen I.M., Schimmer A.D., Reed J.C. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002, 21:3459-3474.
46. Tagawa H., Karnan S., Suzuki R., Matsuo K., Zhang X., Ota A., et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005, 24:1348-1358.
47. Tan T.T., Degenhardt K., Nelson D.A., Beaudoin B., Nieves-Neira W., Bouillet P., et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005, 7:227-238.
48. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
49. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
50. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
51. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007, 67:782-791.
52. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
53. Tromp J.M., Geest C.R., Breij E.C., Elias J.A., van Laar J., Luijks D.M., et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 2012, 18:487-498.
54. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007, 26:3972-3979.
55. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007, 104:19512-19517.
56. Miller L.A., Goldstein N.B., Johannes W.U., Walton C.H., Fujita M., Norris D.A., et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 2009, 129:964-971.
57. Hikita H., Takehara T., Shimizu S., Kodama T., Shigekawa M., Iwase K., et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52:1310-1321.
58. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
59. Vandenberg C.J., Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121:2285-2288.
60. Vaillant F., Merino D., Lee L., Breslin K., Pal B., Ritchie M.E., et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013, 24:120-129.
61. Touzeau C., Dousset C., Le Gouill S., Sampath D., Leverson J.D., Souers A.J., et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014, 28:210-212.
62. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 2013, 163:139-142.
63. Pan R., Hogdal L.J., Benito J.M., Bucci D., Han L., Borthakur G., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014, 4:362-375.
64. Bogenberger J.M., Delman D., Hansen N., Valdez R., Fauble V., Mesa R.A., et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-Azacytidine in myeloid malignancies. Leuk Lymphoma 2014 Apr 8, [Epub ahead of print].